Terminal cancer patients do not receive appropriate radiation therapy

Palliative radiotherapy for end-stage cancer patients is intended to control cancer-related pain and other symptoms and to help patients maintain a good quality of life when long-term cancer control is not possible.

By reducing the number of cancer cells, palliative radiotherapy can ease pain, stop bleeding, and relieve pressure, even when the cancer cannot be controlled. However, for many patients, the treatments are not effective. In addition, if patients are close to death, they may wish to stop treatments if they would like to die at home.

To investigate the adequacy of palliative radiotherapy in end-stage cancer patients, Stephan Gripp, MD, of the University Hospital Duesseldorf in Germany and colleagues evaluated the treatment of patients who were referred for palliative radiotherapy at their hospital from December 2003 to July 2004 and who died within 30 days. The investigators identified 33 such patients.

Radiotherapy was delivered to 91 percent of patients. Half of the patients spent more than 60 percent of their remaining lifespan on radiotherapy, and in only 58 percent of patients was radiotherapy completed. Many physicians overestimated the length of time their patients would survive. Among this group who died within one month, about one in five physicians predicted more than six months survival. In addition, progressive complaints were noted in 52 percent of patients, and palliation or pain reduction was reported by only 26 percent of patients.

The authors concluded that radiotherapy was not appropriately customized to these cancer patients, many of whom did not benefit despite spending most of their remaining life on therapy. Excessive radiotherapy in end-stage cancer patients may reflect overoptimistic prognoses and unrealistic concerns about radiation damage.

“Radiation oncologists have fallen short in accurately determining the life span of terminally ill cancer patients. This has resulted in unduly prolonged radiation therapy regimens that often go uncompleted due to death or withdrawal from treatment,” said Dr. Gripp. He added that physicians need better methods for estimating how long their end-stage cancer patients will live. He also recommended that they use shorter-duration radiation schedules for palliative radiotherapy.

Article: “Palliative radiotherapy tailored to life expectancy in end-stage cancer patients: reality or myth?” Stephan Gripp, Sibylle Mjartan, Edwin Boelke, and Reinhardt Willers. CANCER; Published Online: April 12, 2010 (DOI: 10.1002/cncr. 25112).

Author Contact: To arrange an interview with Dr. Gripp, please contact Susanne Dopheide of the Heinrich-Heine-Universität Press Office:+49 211 81-04173 or susanne.dopheide@med.uni-duesseldorf.de

Media Contact

Claire Greenwell EurekAlert!

More Information:

http://www.cancer.org

All latest news from the category: Health and Medicine

This subject area encompasses research and studies in the field of human medicine.

Among the wide-ranging list of topics covered here are anesthesiology, anatomy, surgery, human genetics, hygiene and environmental medicine, internal medicine, neurology, pharmacology, physiology, urology and dental medicine.

Back to home

Comments (0)

Write a comment

Newest articles

Recovering phosphorus from sewage sludge ash

Chemical and heat treatment of sewage sludge can recover phosphorus in a process that could help address the problem of diminishing supplies of phosphorus ores. Valuable supplies of phosphorus could…

Efficient, sustainable and cost-effective hybrid energy storage system for modern power grids

EU project HyFlow: Over three years of research, the consortium of the EU project HyFlow has successfully developed a highly efficient, sustainable, and cost-effective hybrid energy storage system (HESS) that…

After 25 years, researchers uncover genetic cause of rare neurological disease

Some families call it a trial of faith. Others just call it a curse. The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare condition, but its…

Partners & Sponsors